- Home
- MNPR vs GBLI Comparison
MNPR vs GBLI Comparison
Compare MNPR & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- GBLI
- Stock Information
- Founded
- MNPR 2014
- GBLI 2016
- Country
- MNPR United States
- GBLI United States
- Employees
- MNPR N/A
- GBLI N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- MNPR Health Care
- GBLI Finance
- Exchange
- MNPR Nasdaq
- GBLI Nasdaq
- Market Cap
- MNPR 390.5M
- GBLI 428.9M
- IPO Year
- MNPR 2019
- GBLI 2003
- Fundamental
- Price
- MNPR $99.37
- GBLI $29.85
- Analyst Decision
- MNPR Strong Buy
- GBLI
- Analyst Count
- MNPR 12
- GBLI 0
- Target Price
- MNPR $89.82
- GBLI N/A
- AVG Volume (30 Days)
- MNPR 78.9K
- GBLI 2.6K
- Earning Date
- MNPR 11-07-2025
- GBLI 11-06-2025
- Dividend Yield
- MNPR N/A
- GBLI 4.75%
- EPS Growth
- MNPR N/A
- GBLI N/A
- EPS
- MNPR N/A
- GBLI 1.98
- Revenue
- MNPR N/A
- GBLI $439,280,000.00
- Revenue This Year
- MNPR N/A
- GBLI $5.48
- Revenue Next Year
- MNPR N/A
- GBLI $7.91
- P/E Ratio
- MNPR N/A
- GBLI $14.84
- Revenue Growth
- MNPR N/A
- GBLI N/A
- 52 Week Low
- MNPR $4.50
- GBLI $26.94
- 52 Week High
- MNPR $105.00
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- MNPR 88.79
- GBLI 52.75
- Support Level
- MNPR $72.41
- GBLI $28.46
- Resistance Level
- MNPR $105.00
- GBLI $29.82
- Average True Range (ATR)
- MNPR 7.21
- GBLI 0.44
- MACD
- MNPR 2.86
- GBLI 0.03
- Stochastic Oscillator
- MNPR 89.52
- GBLI 87.42
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.